QSAR-guided design, DFT, molecular docking, and ADMET prediction of novel thiazolidinone-based indole derivatives as potent α-glucosidase inhibitors
Letters in Drug Design & Discovery · 2026-09 · 23 (9) · 100624
DOI: 10.1016/j.lddd.2026.100624 ↗Kurz gefasst
Fachartikel in der Zeitschrift Letters in Drug Design & Discovery, 2026-09. Verfasst von Augustine Onuche Sule und 6 weiteren Autor:innen. Die Arbeit nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
Diabetes mellitus is a global metabolic disorder characterized by postprandial hyperglycemia, posing therapeutic challenges. Inhibiting α-glucosidase is an effective strategy for managing glucose levels. Thiazolidinone-based indole derivatives have potential as α-glucosidase inhibitors, although a comprehensive computational analysis of their structural activity determinants is currently lacking.
Objectives
This study aimed to develop a validated QSAR model for thiazolidinone-based indole derivatives as α-glucosidase inhibitors, design novel analogs from the most effective parent derivative (compound 5), and assess their pharmacokinetic profiles, binding interactions, and electronic characteristics using an integrated computational approach.
Methods
A GA-MLR QSAR model was developed using a dataset of 20 thiazolidinone-based indole derivatives with known α-glucosidase inhibitory activity. New chemical analogs were generated from the most potent derivative, docked into the α-glucosidase structure, and subjected to ADMET profiling after reactivity was evaluated using DFT (B3LYP/6–31 G ** ).
Results
The GA-MLR QSAR model identified three important inhibitory activity descriptors, with predictive performance (R² train = 0.911, Q² cv = 0.832, R² test = 0.697). D3, an analog having a -CF₃ group at the fifth position of the indole ring, showed a predicted IC 50 of 2.72 µM and a docking affinity of −6.2 kcal/mol, while DFT revealed the lowest energy gap (ΔEg = 3.07 eV) and high electrophilicity (ω = 4.23 eV). ADMET profiling predicted no mutagenicity or hERG I inhibition and revealed zero Lipinski violations and adequate gastrointestinal absorption (92.95%); however, D3 and compound 5 were predicted CYP3A4 inhibitors, and all evaluated compounds were predicted hERG II inhibitors.
Conclusion
D3 represents a computationally promising scaffold with predicted α-glucosidase inhibitory activity warranting experimental validation, including α-glucosidase inhibition assays, cytotoxicity studies, CYP450 microsomal stability, and hERG liability assessment. These findings highlight an integrated computational approach for designing thiazolidinone-based indole derivatives as potential antidiabetic agents.
Zitieren
APA
Sule, A. O., Ohiole, M. I., Olatunde, M. A., Obiyenwa, K. G., Olarinoye, E. F., Olatunji, N. O., & Semire, B. (2026). QSAR-guided design, DFT, molecular docking, and ADMET prediction of novel thiazolidinone-based indole derivatives as potent α-glucosidase inhibitors. Letters in Drug Design & Discovery, 23(9), 100624. https://doi.org/10.1016/j.lddd.2026.100624
Vancouver
Sule AO, Ohiole MI, Olatunde MA, Obiyenwa KG, Olarinoye EF, Olatunji NO, et al. QSAR-guided design, DFT, molecular docking, and ADMET prediction of novel thiazolidinone-based indole derivatives as potent α-glucosidase inhibitors. Letters in Drug Design & Discovery. 2026;23(9):100624. doi:10.1016/j.lddd.2026.100624
BibTeX
@article{Sule2026,
author = {Sule, Augustine Onuche and Ohiole, Mary Ikhaote and Olatunde, Modupe Abimbola and Obiyenwa, Kehinde Gabriel and Olarinoye, Elizabeth Funke and Olatunji, Nathaniel Oladoye and Semire, Banjo},
title = {QSAR-guided design, DFT, molecular docking, and ADMET prediction of novel thiazolidinone-based indole derivatives as potent α-glucosidase inhibitors},
journal = {Letters in Drug Design & Discovery},
year = {2026},
volume = {23},
number = {9},
pages = {100624},
doi = {10.1016/j.lddd.2026.100624}
}
EUVIMED